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Background: Patient-reported outcomes (PROs) are commonly collected in clinical trials and should provide
impactful evidence on the effect of interventions on patient symptoms and quality of life. However, it is unclear
how PRO impact is currently realised in practice. In addition, the different types of impact associated with PRO trial
results, their barriers and facilitators, and appropriate impact metrics are not well defined. Therefore, our objectives
were: i) to determine the range of potential impacts from PRO clinical trial data, ii) identify potential PRO impact
metrics and iii) identify barriers/facilitators to maximising PRO impact; and iv) to examine real-world evidence of
PRO trial data impact based on Research Excellence Framework (REF) impact case studies.
Methods: Two independent investigators searched MEDLINE, EMBASE, CINAHL+, HMIC databases from inception
until December 2018. Articles were eligible if they discussed research impact in the context of PRO clinical trial data.
In addition, the REF 2014 database was systematically searched. REF impact case studies were included if they
incorporated PRO data in a clinical trial.
Results: Thirty-nine publications of eleven thousand four hundred eighty screened met the inclusion criteria. Nine
types of PRO trial impact were identified; the most frequent of which centred around PRO data informing clinical
decision-making. The included publications identified several barriers and facilitators around PRO trial design,
conduct, analysis and report that can hinder or promote the impact of PRO trial data. Sixty-nine out of two
hundred nine screened REF 2014 case studies were included. 12 (17%) REF case studies led to demonstrable impact
including changes to international guidelines; national guidelines; influencing cost-effectiveness analysis; and
influencing drug approvals.
Conclusions: PRO trial data may potentially lead to a range of benefits for patients and society, which can be
measured through appropriate impact metrics. However, in practice there is relatively limited evidence
demonstrating directly attributable and indirect real world PRO-related research impact. In part, this is due to the
wider challenges of measuring the impact of research and PRO-specific issues around design, conduct, analysis and
reporting. Adherence to guidelines and multi-stakeholder collaboration is essential to maximise the use of PRO trial
data, facilitate impact and minimise research waste.
Trial registration: Systematic Review registration PROSPERO CRD42017067799.
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Table 1 REF 2014 – Main panel A
Units of assessment
Main panel A 1 Clinical medicine
2 Public Health, Health Services and Primary Care
3 Allied Health Professions, Dentistry, Nursing
and Pharmacy
4 Psychology, Psychiatry and Neuroscience
5 Biological Sciences
6 Agriculture, Veterinary and Food Science
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Patient-reported outcomes (PROs) are increasingly used
in clinical trials to assess the impact of a medical treat-
ment or intervention. PRO assess a range of outcomes
including symptoms, functional health, well-being and
psychological issues from the patients’ perspective, with-
out interpretation by a clinician [1–3]. Between 2007
and 2013, 26,337 (27%) of the clinical trials registered on
ClinicalTrials.gov included PROs [4]. However, there is
growing evidence that there is substantial research waste
in relation to PROs [5, 6]. A recent systematic evaluation
of oncology clinical trials determined that PRO protocol
items were frequently omitted, non-reporting of PRO
trials results was common and PRO publications were
considerable delayed and presented suboptimal stan-
dards of reporting [5]. Thus, important PRO evidence
may not be available to benefit patients and society.
Assessing the impact of research is a complex activity;
however, it is important that the impact of PRO data is
understood as this may inform funding allocations and
demonstrate accountability to government, stakeholders
and society [7]. Impact is defined as “any identifiable bene-
fit to, or positive influence on, the economy, society, public
policy or services, culture, the environment or quality of life
…” (p.26) [8]. A number of reviews describe potential
pathways (i.e. “a way of achieving a specified result; a
course of action’ [9]) to general research impact [8, 10–
33]. However, few studies have investigated the optimal
pathway or methods for augmenting or evaluating specific
impacts of PRO trial data or the extent to which PRO im-
pact is being realised. It is also not clear which is the most
appropriate way to measure PRO impact, or the barriers
and facilitators to realising that impact.
One way of assessing real-world impact is via the United
Kingdom (UK) Higher Education Funding Council for Eng-
land Research Excellence Framework (REF) impact case
studies. During the REF 2014 exercise, UK higher education
institutions submitted impact case studies: narratives that
described the impact of research conducted during a spe-
cific time-period, including a number of case studies de-
scribing clinical trials involving PROs. REF case studies
present meaningful, far-reaching and properly articulated
impact that is demonstrated through convincing evidence.
The impact presented focuses on the benefits of the re-
search rather than on the pathways of research impact,
allowing the assessment of real-world impact on society
[34]. Examination of these case studies can enhance under-
standing of the best methods for maximising and measur-
ing PRO research impact, not only in the UK, but also
internationally since a number of the studies described in
REF are international studies [10, 35].
Therefore, the study had four objectives. First, to conduct
a systematic review of the literature to: i) determine the
range of potential impact that may arise from clinical trialPRO clinical trial data, ii) identify potential PRO impact
metrics iii) identify barriers/facilitators to maximising PRO
impact and; iv) to examine REF 2014 impact case studies to
explore real-world evidence of PRO trial data impact.
Methods
This systematic review was registered on the PROSPERO
database (CRD42017067799) and results are reported in
accordance with PRISMA guidelines [36].
Search strategy
Systematic review
Two reviewers (SCR and OLA) systematically and independ-
ently searched MEDLINE (Ovid), EMBASE, HMIC and
CINAHL+ databases (inception to December 2018) for arti-
cles discussing the impact of PRO data collected from clin-
ical trials from inception to December 2018 (see Additional
file 1 for the full search strategy). The authors (SCR/MC/
DK) designed the search strategy with input from a Univer-
sity of Birmingham Information Specialist. In addition, the
keywords ‘patient reported outcome measure*’, ‘PROs’,
‘PRO’, ‘PROM’, ‘PROMS’, ‘HRQOL’, ‘HRQL’, ‘quality of life’,
‘impact’ and ‘clinical trial*’ were searched on Google Scholar,
where the initial 100 results were screened. Only the first
100 results (10 pages) were revised, as article relevance di-
minishes with each page of results [37]. Lastly, additional
publications (n= 3) were sought through communication
with methodological PRO experts facilitated by MC/DK.
Hand-searching of reference lists and citation searches of the
included publications was also conducted to identify add-
itional relevant articles.
REF 2014 impact case studies
The keywords “trial*” and “quality of life” or “patient
reported outcome*” were introduced in the REF 2014
database. The search strategy was restricted to: i) Unit of
assessment: main panel A (see Table 1 for further detail),
ii) Summary impact type: ‘health’ and iii) Research
subject area: medical and health sciences.
Eligibility criteria
Systematic review publications were deemed eligible if they
discussed research impact in the context of PRO clinical trial
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impact (and pathways to impact) thought to be associated
with PRO findings, proposed methods for measuring such
impact and perceived barriers/facilitators to generating PRO-
specific research impact. Publications were excluded if: i)
solely focused on PROs used in routine clinical practice as
the focus of this review was on the proposed PRO impact
from trials; ii) trial publications reporting PRO results as the
focus was research impact rather than primary results; or iii)
conference abstracts. REF 2014 impact case studies were eli-
gible if they included a trial in which PRO data were col-
lected. There were no language restrictions.
Data screening
Systematic review
The screening process was conducted independently by
two reviewers (SCR and OLA). Citations were down-
loaded into Endnote® software (version X7.3.1) and du-
plicates deleted. Records were screened by title and
abstract. Potentially relevant articles were identified for
further full-text screening (SCR and OLA). Discrepan-
cies were resolved through discussion with a third re-
viewer (MC/DK/AS) if required.
REF 2014 impact case studies
The screening process was also conducted independ-
ently by SCR and OLA. The case studies were down-
loaded into a Microsoft Excel spreadsheet. Records
were screened by title and summary of the impact.
Relevant case studies were selected for further full-
text screening (SCR and OLA). Discrepancies were re-
solved through discussion, with a third reviewer (MC/
DK/AS) as necessary.
Data extraction/coding
Systematic review
Data extraction was done after the final selection of the
included articles. SCR and OLA independently identi-
fied text excerpts that provided information on PRO-
specific impact types, pathways, metrics, barriers or fa-
cilitators from the systematic review. Both reviewers in-
dependently imported text excerpts into a qualitative
data analysis software package (QRS NVivo 11). They
generated categories independently using descriptive
coding under the directed content analysis framework
[38]. The ‘pathways to research impact’ framework [10]
was deductively applied to the data in order to identify
types of impact and impact metrics. Data which did not
fit within the existing framework were added to a ‘mis-
cellaneous’ category. ‘Influence on policy-making’ was
the only impact category discussed by the articles in-
cluded in the systematic review. Subsequently, the data
coded into this impact category was organised into sub-
groups. Through deductive coding, the following typesof impact were identified: ‘inform clinical practice’, ‘in-
form clinical guidelines’, ‘inform clinical decision-
making’, ‘inform health policy’ and ‘inform shared
decision-making’.
Inductive coding was undertaken to describe and in-
terpret more detailed codes within the ‘influence on
policy-making’ and miscellaneous categories. The follow-
ing types of impact were identified through inductive
coding: ‘support drug approval’, ‘support pricing deci-
sions’, ‘support reimbursement decisions’ and ‘inform
consent for treatment’. In addition, inductive coding was
used to identify further impact metrics, and barriers and
facilitators to PRO trial impact. Development of over-
arching themes occurred after the coding process and
collation of codes. The following details were also ex-
tracted from all the included publications: author, publi-
cation year, journal, methodology, study focus and type
of PRO data impact.
REF 2014 impact case studies
Deductive and inductive was also undertaken to identify
types of impact, impact metrics and barriers and facilita-
tors among the REF case studies. In addition, the follow-
ing details were extracted from the REF 2014 case
studies: name, submitting institution and clinical area;
trial name and year of publication, trial design, leading
study centre, trial phase, trial primary and secondary
outcomes, PRO instrument, significance of primary and
secondary trial outcomes and type of impact. Further-
more, type of impact was further classified as either: i)
direct PRO impact, where there was evidence of a direct
link between PRO trial findings and subsequent impact.
ii) Indirect PRO impact, where a trial including PROs
subsequently led to impact, but it was not possible to
directly attribute this impact to the PRO findings over
and above the other trial outcomes; or iii) no evidence
of PRO impact, where a trial including PROs failed to
lead to impact. SCR and OLA independently piloted the
coding frames, following discussion with MC/DK/AS/
CM to resolve discrepancies. Finally, systematic review
and impact case studies coding frames were validated by
the co-authors MC/DK/AS/CM, who possess expertise
in PRO clinical trial data, research impact and qualitative
data analysis.
Results
Systematic review
Included studies
The search strategy retrieved 11,377 citations from
MEDLINE (Ovid), EMBASE, HMIC, and CINAHL+;
100 citations were returned using Google Scholar and 6
through expert communication (PRISMA flow diagram,
Additional file 2). Eight thousand eight hundred
seventy-seven citations were excluded following review
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were assessed. Sixteen articles were excluded at this
stage, as they assessed PRO data in routine care as an
intervention. An additional 23 articles were included
following hand-searching of reference lists and citation
searches. In total, 39 eligible publications were included
in the synthesis.Study characteristics
The characteristics of the 39 included publications are
summarised in Appendix 1. Fifteen (38%) publications
were classified as systematic reviews, 11 as literature re-
views (28%), eight (20%) as commentaries, three as
qualitative studies and two as guidance papers. Non-
English publications were identified through the differ-
ent bibliographic methods used.PRO impact types and pathways to impact
The included publications identified nine types of
impact that authors proposed could be associated with
PRO trial findings. These included; ‘informing clinical
practice’, ‘informing clinical guidelines’, ‘informing
health policy’, ‘supporting drug approval’, ‘supporting
pricing decisions’ and ‘supporting reimbursement deci-
sions’, ‘informing clinical decision-making’ and ‘inform-
ing shared decision-making’ and ‘informing consent for
treatment’ (Fig. 1).
The majority of publications (69%) focused on the po-
tential impact of PRO trial results on clinical decision-
making [7, 39–67]. Clinical decision-making refers to
the clinical evidence-based decisions made regarding
individual patient care by the clinicians whilst consid-
ering clinician’s knowledge, skills and attitudes, resources
available and the patient’s own concerns, values and
preferences [68]. 15% of the publications considered the
benefits of using PRO trial results to inform clinical
practice [53, 56, 62–64]. Clinical practice refers to the
healthcare services provided to patients at an organisa-
tional level, which are normally adopted following clin-
ical practice guidelines [69].
One paper focused on the impact of PRO trial results
on clinical guideline development [46] and one paper
focused on PRO data use in the development of health-
care policy [7]. Several publications recognised the im-
pact of PRO trial findings on drug approval (29%)
[49, 66, 70–76], pricing (7%) [61, 72, 77] and reim-
bursement decisions (20%) [7, 65, 66, 72, 75, 77, 78].
Eight publications (20%) discussed the influence of
PRO data on pharmaceutical labelling claims by the
Food and Drug Administration (FDA) and European
Medicines Agency (EMA) [49, 66, 70–76]. An ex-
ample given by one author was ruxolitinib (Jakafi™):
an oral inhibitor to treat intermediate or high riskpatients with myelofibrosis. This was the first FDA
approved oncology drug that used PROs as an end-
point and followed FDA guidance to support a PRO-
based labelling claim [78]. The oncology drug was ap-
proved based on reduction in spleen volume and im-
provement in symptom severity (e.g. weight loss,
night sweats, itching, abdominal pain/discomfort,
bone pain, cough, inactivity, early satiety and fever),
as measured by the Myelofibrosis Symptom Assess-
ment Form (MFSAF) v2.0 Total Symptom Score.
Lastly, one paper discussed the impact of PRO data
on shared decision-making [79] and two papers (2%)
on informing consent for treatment [44, 54]. The
types of potential PRO impact proposed in each pub-
lication are summarised in Fig. 1 and described in
Appendix 2. Shared decision-making is also important
and four publications outlined the potential benefits
of including PRO findings alongside other outcomes
such as survival. This allowed patients and their clini-
cians to make an informed joint decision about treat-
ment preferences and symptom management based
on mutual understanding of treatment objectives and
expectations [1–4].
PRO impact metrics
Based on the review of the 39 included publications, two
impact metrics were identified. Number of pharmaceut-
ical labelling claims approved, mentioned by eight au-
thors [70–76, 80] and number of promotional labelling
claims, discussed by one author [70].
Barriers to impact
Authors identified different perceived methodological
barriers to PRO trial impact, which fell within the fol-
lowing categories: ‘trial design’, ‘conduct and analysis’,
‘reporting’ and the ‘use of PRO data in practice’.
Trial design
Suboptimal PRO-specific trial design was cited by a large
number (n = 22, 56%) of publications as a major barrier
to realising PRO trial impact [40–43, 45–47, 49, 51, 52,
55, 62–64, 70, 72, 73, 76, 78, 81–83]. Particular areas of
concern were selection of inappropriate or invalid PRO
measures (n = 10, 52%). Lack of development of PRO
cross-cultural items (n = 2, 9%). Broader methodological
issues leading to potential bias and which may hinder
PRO data use include allocation concealment, random-
isation, blinding of participants and personnel and blind-
ing of outcomes assessment (n = 7, 18%).
Conduct and analysis
Authors also highlighted that the way the trial was con-
ducted and type of analysis carried out could act as an
impact barrier. Over a third of publications (n = 12,
Fig. 1 Proposed PRO impact types
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trial conduct and analysis [40, 41, 56, 57, 62, 63, 70,
72, 73, 75, 78, 83]. The most frequent barriers men-
tioned by authors were low PRO compliance rates
(n = 10, 83%), lack of personnel training on adminis-
tration of PRO instruments (n = 3, 25%), incomplete
follow-up of HRQL assessment (n = 2, 16%), selection
of inappropriate statistical methods to handle missing
data (n = 2, 16%).Reporting
Incomplete or suboptimal reporting of PRO trial data
was cited by 23 (65%) publications as a barrier to re-
search impact if PRO trial findings and generalisability is
not clearly presented [7, 38–43, 45–53, 56, 57, 63, 64,
72, 82, 83]. The most common barriers to impact were
failure to report: the rationale for the chosen PRO in-
strument (n = 10, 43%), mode of administration (n = 10,
43%).Use of PRO data in practice
Adoption of PRO trial findings into clinical practice was
identified as somewhat problematic by 17 (43%) of the
publications [39–41, 43, 45, 46, 52, 54–56, 61, 63, 64, 75,
78, 81, 82]. Key issues included lack of training/practice
for clinicians on interpreting PRO data (n = 11, 64%) and
lack of familiarity with PRO measures (n = 7, 41%).Facilitators to impact
The review of the included articles identified a number
of suggested facilitators purported to enhance the prob-
ability of realising PRO specific impact. Two (5%) au-
thors suggested strict adherence to the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) initiative to improve the completeness of
trial protocols and reduce risk of bias [51, 62]. Eight
(18%) authors proposed adherence to the Consolidated
Standards of Reporting Trials (CONSORT) PRO Exten-
sion statement [7, 51–53, 56, 62, 64, 83] and two (5%)
authors to the CONSORT statement [7, 51], in order to
enhance transparency and complete reporting of PRO
clinical trials. A detailed summary of the barriers and fa-
cilitators highlighted by the included publication are pre-
sented in Table 2, which includes additional resources
identified by communication with methodological PRO
experts (MC/DK).REF 2014 impact case studies
Examples of clinical trial PRO impact were explored
using REF2014 case studies. These identified a range of
impact metrics.Included studies
The search strategy yielded 209 REF 2014 impact case
studies (PRISMA Flow Diagram, Additional file 3). Case
studies were excluded if they did not include a clinical
trial or the clinical trials did not incorporate a PRO
element, meaning 69 relevant case studies were subse-
quently included in the analysis.PRO clinical trials characteristics
The characteristics of the PRO clinical trials included
across the eligible REF 2014 case studies are detailed in
Table 3.
Full details of the included case studies are available in
Additional file 4. The assessment of the PRO trial met-
rics was considered using the ‘pathways to research im-
pact’ framework [10]. Following this, two new additional
impact metrics were identified, cost-effectiveness and
drug/device approval. The summary of the PRO impact
metrics is depicted in Fig. 2.Real-world evidence of PRO impact
Assessment of the 69 eligible case studies determined
that (n = 12, 17%) appeared to lead to direct demon-
strable PRO impact, (n = 12, 17%) showed evidence of
indirect PRO impact and (n = 45, 66%) provided no
evidence of PRO impact (Fig. 2). Trials that included
PROs as primary outcome (50%) reported a larger
number of trials leading to direct impact than those
trials that had PROs as secondary outcome (83%).Direct PRO impact
The most common types of direct PRO impact pre-
sented across the case studies included: number of pub-
lications (n = 12, 17%), citation rates (n = 12, 17%),
changes to international guidelines (n = 5, 7%), contribu-
tion to national guidelines (n = 4, 6%), contribution to
evidence of cost-effectiveness (n = 3, 4%) and informing
drug approval (n = 2, 3%). In addition, several case stud-
ies demonstrated more than one type of impact.
Indirect PRO impact
The most common types of indirect PRO impact
included: number of publications (n = 12, 17%), citation
rates (n = 12, 17%), changes to national guidelines (n = 10,
14%), contribution to international guidelines (n = 9, 13%)
and national practice (n = 9, 13%) and contribution to evi-
dence presented in conferences, seminars and workshops
(n = 5, 7%).
Absence of evidence around PRO impact
The assessment of the included case studies demon-
strated that the impact of PRO trial data is not usually
Table 2 Barriers and facilitators to maximising PRO trial data
Barriers to impact Impact Facilitators
PRO trial design
Authors not using/citing guidelines to design PRO trials [69, 75, 76] ●SPIRIT
●SPIRIT-PRO Exta
Selection of inappropriate PRO time frames of assessment [38, 42, 44, 58] ●SPIRIT
●SPIRIT-PRO Exta
Failure to define PRO/HRQL endpoints [47] ●SPIRIT-PRO Exta
Selection of inappropriate or invalid PRO measures
[42, 44, 50, 52, 54, 57, 60, 66, 67, 69]
●SPIRIT-PRO Exta
●ISOQOL Minimum Standards for PRO Measures in patient-centered
outcomes and comparative
effectiveness researcha
Inappropriate PRO sample size and population [38, 48, 54, 56, 59] ●SPIRIT
●SPIRIT-PRO Exta
Issues of bias due to allocation concealment (selection bias), random
sequence generation (selection bias), blinding of participants and
personnel (performance bias) and blinding of outcomes assessment
(detection bias)
[57, 68, 69, 75, 76, 79, 82]
●SPIRIT
Lack of evidence of PRO translation or cross-cultural validation [53, 57] ●SPIRIT-PRO Exta
PRO trial conduct and analysis
Low PRO compliance rates [38, 39, 42, 44, 50, 60, 61, 77, 79, 82] ●SPIRIT-PRO Exta
●SISAQOLa
Lack of personnel training on administration of PRO instruments
[44, 57, 61]
●SPIRIT-PRO Exta
●SISAQOLa
Lack of communication between researchers and administrators
regarding PRO questionnaires involved in the trial [44]
●SPIRIT-PRO Exta
●SISAQOLa
Lack of standardisation of the PRO questionnaire administration
process [44, 61]
●SPIRIT-PRO Exta
●SISAQOLa
Lack of patient adherence to the PRO component of the study
due to questionnaire length or irrelevant content [44, 52, 61]
●SPIRIT-PRO Exta
●SISAQOLa
PRO trial reporting
Authors not using/citing guidelines to report PRO trials
(e.g. CONSORT PRO Extension) [54, 69, 75, 76]
●CONSORT
●CONSORT-PRO Ext
Failure to report the a priori PRO hypothesis
[39, 50, 54, 58, 59, 62, 63, 69]
●CONSORT
●CONSORT-PRO Ext
●SPIRIT-PRO Ext
Failure to report baseline PRO compliance [39, 50, 59, 62, 69] ●CONSORT
Failure to report rationale for the chosen PRO instrument
[7, 39, 44, 50, 54, 58, 62, 69, 72, 76]
●CONSORT-PRO Ext
●SPIRIT-PRO Ext
Failure to report mode of administration of the PRO instrument
[44, 47, 48, 50, 54, 58, 62, 63, 75, 76]
●CONSORT-PRO Ext
●SPIRIT-PRO Ext
Failure to report timing of PRO assessment [37, 58, 59] ●CONSORT
●SPIRIT-PRO Ext
Failure to report methods of PRO data collection [62, 63] ●CONSORT
●CONSORT-PRO Ext
Failure to report clinical significance of PRO findings
[39, 40, 47, 56, 59, 62, 67, 75]
CONSORT-PRO Ext
Reporting levels of missing PRO data [7, 39, 52, 58, 59, 62] ●CONSORT
●CONSORT-PRO Ext
Failure to report statistical methods dealing with missing PRO data
[39, 54, 56, 58, 62, 63, 69, 75]
●CONSORT
●SPIRIT-PRO Ext
Failure to report generalisability of PRO trial results in the context
of clinical outcomes [54, 56, 69, 76, 82]
CONSORT-PRO Ext
Selective reporting of PRO results [7, 75, 76] ●CONSORT
●SPIRIT-PRO Ext
Rivera et al. Health and Quality of Life Outcomes          (2019) 17:156 Page 7 of 19
Table 2 Barriers and facilitators to maximising PRO trial data (Continued)
Barriers to impact Impact Facilitators
Discrepancies between PRO protocol and PRO trial report [44] ●CONSORT
●SPIRIT-PRO Ext
Failure to report PRO data in the main trial publication
[47, 48, 54, 59, 63, 72]
●Publication of HRQL and other clinical outcomes in
the main trial report [48, 67, 69, 72]
Late publication of PRO trial results and in a different journal
to the main publication [42, 48, 56, 67, 72, 77]
●Publication of secondary and timely PRO publication [63, 69]
Journal word restrictions [54, 69] ●Journals should allow space to report HRQL data alongside
other clinical outcomes [50]
Barriers to uptake of PRO trial results in practice
Lack of familiarity with PRO measures [42, 44, 45, 50, 60, 67, 71] ●PROlearna
●SPIRIT-PRO Ext
●Provide training to clinicians to gain confidence regarding
the validity and reliability of HRQL instruments [67]
Lack of training/guidance for clinicians on interpreting PRO data
[40, 42, 44, 45, 48, 50, 53, 58, 66, 67, 69]
●PROlearna
●Training for clinicians to understand clinical interpretation of
HRQL data [48, 50]
●Clinician’s checklist for reading and using an article about
patient-reported outcomesa
Clinicians concerns about the PRO results being biased by
missing data [77]
●PROlearna
●Provide training to clinicians to gain confidence regarding
the validity and reliability of HRQL instruments [67]
●Clinician’s checklist for reading and using an article about
patient-reported outcomesa
Lack of evidence of generalisability of PRO/HRQL results
[42, 53, 67, 71]
●CONSORT
●Clinician’s checklist for reading and using an article about
patient-reported outcomesa
Concerns that the PRO results were chance findings arising
from multiple testing [77]
●PROlearna
●Provide training to clinicians to gain confidence regarding
the validity and reliability of HRQL instruments [67]
●Clinician’s checklist for reading and using an article about
patient-reported outcomesa
Researchers failure to present PRO data in a way that is
accessible to patients and clinicians [54, 69]
Use of graphical methods to present PRO results [42, 44, 48, 50]
●Stakeholder-driven, evidence-based standards for presenting
PROs in clinical practicea
Lack of time to discuss PRO outcomes with patients [67] ●PROlearna
●Provide consistent and improved HRQL data reports and a
summary of the clinical implications of the HRQL results [67]
●Provide training to clinicians to gain confidence regarding
the validity and reliability of HRQL instruments [67]
Overburden of staff, clinicians, participants and resources
[42, 44, 56, 61]
●SPIRIT-PRO Exta
ISOQOL Minimum Standards for PRO Measures in patient-centred outcomes and comparative effectiveness research [83]. CONSORT (Consolidated Standards of
Reporting Trials) [84]. CONSORT-PRO Extension [58]. SPIRIT (Standard Protocol Items: Recommendations for Interventional Trial) [85]. SPIRIT-PRO Extension [3].
SISAQOL (The Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data) [86]. Stakeholder-driven, evidence-
based standards for presenting PROs in clinical practice [87]. Clinician’s checklist for reading and using an article about patient-reported outcomes [88]. PRO Learn
[89]. Ext Extension
aAdditional resources identified through expert communication
Rivera et al. Health and Quality of Life Outcomes          (2019) 17:156 Page 8 of 19captured in the long-term, specifically under the impact
categories health and health system impacts, health re-
lated and social impact and economic impact.
Discussion
This manuscript is the first to present a systematic re-
view aimed at identifying the potential types of PRO
trial impact alongside real-world evidence of impact. It
will allow researchers, clinicians, funders and policy-makers to consider pathways to research impact before
conducting PRO trial research and to identify metrics
to assess impact prospectively. In the same way, it will
allow PRO stakeholders to consider facilitators at the
design, conduct, analysis and reporting stages whilst
avoiding recurrent barriers to generating PRO-specific
impact and minimising research waste. High quality
clinical trials involving PROs may lead to benefits for
patients and society.
Table 3 PRO clinical trials characteristics
Trial characteristics Number of trials, (%)
Trial phase
I 0
I/II 1 (1.4)
II 1 (1.4)
III 24 (34)
Other 3 (5.7)
Not specified 40 (57)
Leading study centre
UK 62 (89)
International 7 (11)
Trial design
International multicentre study 21(30)
PRO outcome
Primary outcome 17 (24)
Secondary outcome 35 (50)
Both 11 (15)
PRO measures used
SF-36 17 (24)
EQ-5D 12 (17)
HADS 9 (13)
VAS 9 (13)
EORTC QLQ-C30 3 (4)
Other 70a
aNumber of different PRO measures identified – eCase studies characteristics
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fied (Fig. 1): informing clinical practice, informing clin-
ical guidelines, informing health policy, supporting
drug approval, supporting pricing and supporting re-
imbursement decisions, informing clinical and shared
decision-making and informing consent for treatment.
Only four impact metrics were proposed to measure
the impact of PRO data, number of pharmaceutical
claims and promotional labelling claims and inform
drug/device approval and cost-effectiveness. Further
research to formalise PRO-specific impact metrics is
required.
Authors suggested that potential barriers to the use
of PRO trial findings to inform healthcare decision-
making and patient care included poor quality trial de-
sign, conduct, analysis, reporting and uptake in practice
[55]. Several of the barriers comprised within ‘uptake of
PRO trial results in practice’ (Table 2) are not unique
to PRO clinical trials. These challenges are also en-
countered in the implementation of PRO data col-
lected in routine clinical practice to inform patient
care or for audit/benchmarking purposes. For in-
stance, ‘high levels of missing data’ ‘overburden ofstaff, clinicians, participants and resources’, ‘lack of
training/guidance for clinicians on interpreting PRO
data’ are challenges commonly faced in routine prac-
tice [84, 85]. Furthermore, it is important to note that
many of these challenges are not unique to PRO
data/trials. Greater efforts are required to improve
outcome selection, collection and reporting in both in
trials and routine care [86, 87].
Suboptimal reporting of PRO trial data was the most
discussed barrier (65%), which might hinder the maxi-
misation of PRO trial findings. Therefore, addressing
poor and incomplete reporting is essential, as it is uneth-
ical to waste research funding, resources and patients’ ef-
forts and time invested during the collection PRO trial
data [5, 6]. In recent years, a number of methodological
guidelines have been developed to address the different
barriers highlighted by this systematic review. These in-
clude: the SPIRIT-PRO Extension to improve the com-
pleteness of trial protocols [3]; The ongoing work of the
SISAQOL Consortium to standardise the analysis and
interpretation of PRO and quality of life from oncology
clinical trials [88]; CONSORT-PRO Extension to facili-
tate optimal reporting guidance of trials that include
PROs as primary or secondary outcome [46] and; the
work carried out by Snyder et al. (2017) to present PRO
trial findings [89]. The adoption of these guidelines has
the potential to improve the design, conduct, analysis
and report of PRO trials thus ensuring that high-quality
data that may benefit patients and society are obtained
from trials. The uptake of these guidelines is currently
being promoted through PROTEUS (Patient-Reported
Outcomes Tools: Engaging Users & Stakeholders) Con-
sortium, which is funded by the US Patient Centred
Outcomes Research Institute (PCORI) [90].
The literature suggests that adherence to guidelines
should be endorsed/mandated by journals/editors in
order to ensure high quality PRO data through the
trial design, implementation, analysis and reporting
stages. In addition, the FDA [2] and EMA [91] pro-
vide guidance to sponsors on reporting of PRO in-
strument development, measurement properties,
implementation, analysis, and interpretation used to
support drug approval and pharmaceutical labelling
claims in the United States and Europe, respectively.
Additional facilitators identified to maximise the real-
isation of impact in practice were reporting of PRO
results adequately within the main trial publication,
whilst considering journals word restrictions [43, 52,
53, 56, 64] and clinicians receiving training/guidance
on interpretation of PRO data [41, 43, 52, 63]. Thus,
it is essential that funders, ethics committees, journal
editors and trial researchers proactively work together
to ensure that PRO studies follow optimal design,
conduct and analysis and reporting.
Fig. 2 PRO trial impact metrics. *Additional PRO impact metrics identified. **There was not direct mention of this impact metric within the REF
2014 case studies; however, ‘drug approval’ could embrace the concept of patents granted/licenses awarded and brought to the market. Impact
metrics were drew upon the ‘pathways to research impact’ framework [6]
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Table 4 Practical guide for researchers
The Cardiac Resynchronisation — Heart Failure (CARE-HF) trial
demonstrated that the cardiac resynchronisation therapy reduced the risk
of complications and death among patients with left ventricular systolic
dysfunction and cardiac dyssynchrony who had moderate or severe heart
failure [85, 86]. In addition, as measured with the EQ-5D and Minnesota
Living with Heart Failure Questionnaire (MLWHF), the therapy was
associated with quality of life and symptoms improvement [86].
●The main trial publication was characterised for complying with the
different facilitators identified by the systematic review and for adhering
to the SPIRIT PRO Extension and CONSORT PRO Extension guidelines
despite these guidelines being published subsequently.
●Low rates of PRO missing data (8%) and statistical methods for dealing
with missing data were reported.
●The PRO data was included in the main RCT report and alongside
other clinical data [87]. In addition, there were detailed and timely
secondary PRO publications [86, 88, 89].
Attributing impact directly to PRO data is difficult given the survival
benefit; however, this well designed, conducted, analysed and reported
trial led to impact that could be measured through the following
impact metrics:
●In the short term, PRO results were included in the main trial
publication, [87] which led to 4927 citations by January 2018. At least 4
additional PRO trial publications are available.
●In the mid-term, PRO trial findings were incorporated in clinical guide-
lines and health policy at national and international level: NICE in the
UK, [90] the European Society of Cardiology, [91] the European Society
of Cardiology in Canada, [92] Brazil, [93] and USA [94]. Therefore, the use
of CRT influenced the healthcare practice at national and international
level by providing the CRT to patients with heart failure and
dyssynchrony.
●In the long-term, an additional study assessing the effects of the CARE-
HF trial on quality of life demonstrated that the device improved quality
of life and symptoms and improved survival among the users [88]. In
addition, PRO results informed the cost-effectiveness analysis of the
intervention and the production of the device, [89, 95] which led to in-
creased income from industry: ‘the world market for CRT devices is pro-
jected to grow to $2.8 billion annually by 2015’. [81] The cost-effectiveness
analysis demonstrated that CRT is cost-effective when compared with
medical therapy alone (MT). In the same way, CRT plus cardioverter-
defibrillator is more cost-effective when compared to CRT + MT.[95]
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have included information on PRO trial data impact,
we explored whether evidence of impact could be iden-
tified from REF 2014 impact case studies as by their na-
ture, they present an opportunity for researchers to
highlight the impacts of their research. Sixty-nine REF
2014 case studies included a trial where PRO data were
collected. Of these, 24 (34%) presented evidence of
PRO trial impact that was classified as direct or indir-
ect impact. Direct attribution of impact to PRO trial
data was possible in 12 trials, most commonly
informing national and international clinical guide-
lines. A number of potential impact categories are
currently unrealised or under reported. This could be
attributed to the fact that some of the PRO trials as-
sociated to the case studies have been published in
the last years, which limits demonstration of PRO
trial impact in the mid and long-term [10]. Further-
more, it was often difficult to unpick the exact contri-
bution of PRO data to this impact as they were
commonly combined with ‘clinical’ outcome data.
The REF 2014 case study ‘Heart failure: Improving the
quality of life and survival of heart failure patients
through Cardiac Resynchronisation Therapy’, submitted
independently by the University of Birmingham [92] and
Hull [93] is described below (Table 4) to illustrate the
different facilitators that might help translating PRO
findings into clinical practice. This example was chosen,
as it is one of the case studies that have led to most var-
ied impact and will provide researchers a useful guide
about how to maximise PRO trial data and reduce re-
search waste (Fig. 3).
However, reported barriers and facilitators in the lit-
erature focused predominantly on the PRO clinical trial
design, conduct and analysis stages. There was a dearth
of information on how to address barriers to generating
PRO trial impact in practice. Additionally, identified im-
pact was mainly focused on primary research (e.g. publi-
cations, citations and conference). There was little
attention on policy-making, health & health systems,
health related & societal and economic impact, which is
generally realised in the mid and long term. Thus, fur-
ther research in this area is required to identify facilita-
tors to maximise PRO trial impact in the longer term.
This will be achieved through interviews with inter-
national stakeholders in order to explore in-depth per-
ceived barriers and facilitators to effective dissemination
and impact on healthcare decisions and patient care.
Work will be conducted to refine the ‘pathways to re-
search impact’ framework in the context of PRO trial
impact. In addition, it is important to mention that it is
well established that certain impact categories (e.g. pri-
mary research impact via publications) are easier to
measure than others (e.g. societal impact), which canlimit the number of available impact metrics to measure
the impact of PRO trial data.
Limitations
This systematic review summarised the different types
of impact thought to be associated with PRO trial
findings and proposes metrics to measure impact in
practice. The main limitation was that due to poor
indexing, over half of the included publications were
identified through hand-searching of references lists
and citation searches methods rather than databases
searching. Therefore, some relevant publications
might not be included in this article if they failed to
mention a type of impact in the title/abstract. How-
ever, we made efforts to identify all the relevant pub-
lications. The search strategy adopted did not include
the search term ‘self-rated health’, which could have
led to the exclusion of relevant articles. Nonetheless,
our search strategy was informed by the Oxford
PROM Group Construct & Instrument Type Filter
Fig. 3 CARE-HF Trial Pathways to PRO Trial Impact. Logos reproduced with permission of ESC and ACC
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of this systematic review. Although there were no lan-
guage restrictions, we did not systematically search
non-English databases. In addition, a formal quality
appraisal was not undertaken to assess the quality of
the studies included. We acknowledge that a signifi-
cant amount of the evidence we found was based on
expert opinion, which does not rank highly in the evi-
dence hierarchy. Furthermore, a small number of the
included studies were discussed by different authors,
which may have influenced the frequency counts.
However, this does not affect the conclusions of this
systematic review.
The ‘pathways to research impact’ framework was
used to measure the impact of PRO trial data. This
framework was selected as it synthetises all the exist-
ing types of healthcare research impact and metrics
(Fig. 2). However, not all the types of impact outlined
by the framework are relevant to PRO trial data (e.g.
human rights and United Nation Millennium Devel-
opment Goals). The REF is an expert review process
solely focused on the UK HEIs, which may limit the
generalisability of the impact of the PRO data, al-
though 30% of the trials were categorised as inter-
national trials. In some instances, it was not possibleto confirm the impact described by the REF 2014 im-
pact case studies, as there was no access to some
sources provided. It is important to consider that the
case studies had word count restrictions, which could
have led to under reporting of impact. In addition,
the majority of the articles included in the first sec-
tion of the systematic review focused on oncology.
Therefore, the findings presented in this study can
only be generalised to oncology PRO clinical trials.
Conclusion
This review provides a summary of the different types
of potential PRO impact identified in the literature,
supported by real-world examples. The impact of
PRO clinical trials can be attributed to PRO results
and measured through different impact metrics. It is
essential that researchers and authors design, conduct
and analyse and report high quality PRO trial results
and; proactively tackle barriers to PRO impact in
order to maximise the impact of PRO clinical trials in
the short, mid and long term to fully realise benefits
for society. Adherence to guidance and multi-
stakeholder collaboration is essential to maximise the
utilisation of PRO trial data, while minimising re-
search waste and maximising future patient care.
Appendix 1
Table 5 Study characteristics of the literature review
Author Journal Publication type Publication focus Types of PRO impact discussed
Revicki et al.
(2000) [38]
Quality of Life Research Guidance paper Recommendations on use of HRQL data to
support labelling and promotional claims
Informing drug approval
Bottomley et al.
(2003) [39]
American Society of
Clinical Oncology
Systematic review HRQL in Non-small-cell lung cancer Influencing clinical decision-
making
Efficace et al.
(2003) [40]
Journal of Clinical
Oncology
Guidance paper A checklist for evaluating HRQL in prostate
cancer trials
Informing clinical decision-
making
Goodwin et al.
(2003) [41]
Journal of the National
Cancer Institute
Literature review HRQL in breast cancer trials Informing clinical decision-
making
Bjordal
(2004) [42]
Annals of Oncology Literature review Impact of HRQL assessments within trials
on clinical practice
Informing clinical decision-
making
Arpinelli and Bamfi
(2006) [43]
Health and Quality of Life
Outcomes
Commentary PRO trial data in drug development Informing drug approval
Informing reimbursement
decisions
Informing pricing decisions
Avery and Blazeby
(2006) [44]
World Journal Surgery Systematic review HRQL in breast, prostate, lung and
colorectal cancer trials
Informing clinical decision-
making
Blazeby et al.
(2006) [45]
Journal of Clinical
Oncology
Literature review HRQL in surgical oncology trials Informing clinical decision-
making
Influencing informed consent
Patrick D. et al.
(2007) [46]
Value in Health Literature review Use of PRO data to support medical
product labelling claims (FDA perspective)
Informing drug approval
Efficace et al.
(2008) [47]
European Journal of
Cancer
Systematic review HRQL in leukaemia trials Informing clinical decision-
making
Gujral et al.
(2008) [48]
Support Care Cancer Systematic review Quality of life after colorectal cancer surgery Informing clinical decision-
making
Parameswaran et al.
(2008) [49]
Annals of Surgical
Oncology
Systematic review HRQL in surgery for esophageal cancer Influencing clinical decision-
making
Influencing informed consent
McNair and Blazeby
(2009) [50]
Expert Reviews
Pharmaeconomics
Outcomes Research
Literature review HRQL in gastrointestinal cancer trials Informing clinical practice
Informing clinical decision-
making
Inform shared decision-making
Au H. et al.
(2010) [51]
Expert Review of
Pharmacoeconomics &
Outcomes Research
Review HRQL in oncology clinical trials Informing clinical decision-
making
Doward L. et al.
(2010) [52]
Health and Quality of Life
Outcomes
Commentary Use of PRO trial data to inform
pharmaceutical labelling claims and payers
Informing drug approval
Informing pricing decisions
Informing reimbursement
decisions
Snyder and Brundage
(2010) [53]
Expert Reviews
Pharmaeconomics
Outcomes Research
Commentary PROs in healthcare policy, research and
practice
Informing clinical decision-
making
Brundage et al.
(2011) [54]
Quality of Life Research Systematic review PROs in Phase III randomised clinical trials Informing clinical practice
Calvert et al.
(2011) [7]
The Lancet Systematic review Quality of life in clinical trials Informing clinical decision-
making
Informing health policy
Informing drug approval
Ganz (2011) [55] Journal of the National
Cancer Institute
Commentary Quality of life measurement in breast
cancer trials
Informing clinical decision-
making
Lemieux et al.
(2011) [56]
Journal of the National
Cancer Institute
Systematic review Quality of life in breast cancer trials Influencing clinical decision-
making
DeMuro et al.
(2012) [57]
Value in Health Literature review Reasons why PRO label claims were rejected
and provide feedback from the regulatory
perspective regarding the use of PROs in
clinical trials
Informing drug approval
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Table 5 Study characteristics of the literature review (Continued)
Author Journal Publication type Publication focus Types of PRO impact discussed
Calvert et al.
(2013) [58]
Health and Quality of Life
Outcomes
Commentary Implications of the CONSORT PRO
extension on clinical trials and practice
Informing clinical practice
Informing clinical guidelines
Informing health policy
Informing clinical decision-
making
Jacobs et al.
(2013) [59]
Quality of Life Research Systematic review HRQL in oesophageal cancer trials Informing clinical practice
Informing clinical decision-
making
Informing shared decision-
making
Zagadailov E. et al.
(2013) [60]
American Health & Drug
Benefits
Literature review Challenges and opportunities of
incorporating oncology PRO trial data into
reimbursement decisions
Informing reimbursement
decisions
Anker et al.
(2014) [61]
European Heart Journal Literature review Cardiovascular PRO clinical trials Informing drug approval
Informing reimbursement
decisions
Dirven et al.
(2014) [62]
European Journal of
Cancer
Systematic review PROs in brain tumour trials Influencing clinical decision-
making
Efficace et al.
(2014) [63]
European Association of
Urology
Systematic review PROs in prostate cancer trials Informing clinical decision-
making
Efficace et al.
(2014b) [63]
European Journal of
Cancer
Systematic review PROs in gynaecological cancer trials Informing clinical decision-
making
Basch E. et al.
(2015) [64]
JAMA Oncology Qualitative study PRO trial data in cancer drugs development Informing drug approval
Nixon et al.
(2015) [65]
Farmeconomia. Health
Economics and
Therapeutic Pathway
Commentary PRO data to support drug development
decision-making
Informing drug approval
Informing reimbursement
decisions
Informing clinical decision-
making
Rees et al.
(2015) [66]
Journal of Cancer Research
and Clinical Oncology
Systematic review PROs in colorectal cancer trials Informing clinical decision-
making
Rouette et al.
(2015) [67]
Quality of Life Research Literature review Oncologists’ perspectives on HRQL in trials
among countries and specialities
Informing clinical decision-
making
Gnanasakthy et al.
(2016) [68]
Journal of Clinical Oncology Literature review PRO labelling for products approved by
the Office of Haematology and Oncology
Products of the FDA
Informing drug approval
Mercieca-Bebber
et al. (2016) [69]
European Journal of Cancer Systematic review PROs in head, neck and thyroid cancer
trials
Informing health policy
Informing clinical practice
Informing clinical decision-
making
Coon C (2016) [70] Clinical Therapeutics Commentary PRO oncology clinical trials Informing drug approval
Hao Yanni et al.
(2016) [71]
Clinical Therapeutics Commentary PRO oncology clinical trials Informing reimbursement
decisions
Informing pricing decisions
Informing clinical decision-
making
McNair et al.
(2016) [72]
PLOS One Systematic review PRO and clinical gastro-intestinal cancer
data in trials
Informing clinical decision-
making
Informing clinical practice
Mott (2017) [73] Oncology and Therapy Qualitative study PROs and lung cancer Informing reimbursement
decisions Informing clinical
decision-making
Sztankay et al.
(2017) [74]
BMC Cancer Qualitative study HRQL in patients with advanced
non-small cell lung cancer
Informing shared decision-
making
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Potential types of PRO impact proposed
Clinical practice, clinical guidelines and health policy
A number of authors discussed the potential influence of
PRO data on clinical practice, clinical guidelines and
health policy. Several authors felt inclusion of PRO data
on clinical guidelines may influence clinical practice, by
fulfilling unmet clinical needs and leading to improved pa-
tient centre care by helping patients make more informed
decisions on their care [44, 48, 51, 58–60, 76]. Three stud-
ies suggested that the inclusion of PRO data in clinical
guidelines might ensure wider acceptance of guideline rec-
ommendations among patients, while enhancing imple-
mentation through health policy [5, 51, 60].
Drug and device approval
Authors reported that PRO data is increasingly used to
provide evidence for drug and device approval, especially
in oncology clinical trials [67, 68]. Eight publications dis-
cussed the influence of PRO data on pharmaceutical la-
belling claims by the Food and Drug Administration
(FDA) and European Medicines Agency (EMA) [44, 62,
64–70]. One publication suggested that PRO data may
inform drug and device approval through communica-
tion of the benefits and harms of the intervention has to
clinicians, patients and other consumers [64].
Pricing and reimbursement decisions
Three publications discussed the influence of PRO data
on pricing decisions [57, 66, 71] and seven on drug re-
imbursement decisions [5, 57, 61, 66, 69, 71, 74]. Au-
thors suggested that inclusion of PRO data provided
valuable information regarding the risk-benefit of new
interventions. Several authors postulated that within the
context of oncology treatment, PRO data have the po-
tential to identify costly events reported by the patients
in the trials. Hence, interventions with reduced toxicity
and added PRO benefit may influence payer decision-
makers [72]. Additionally, the inclusion of patient advo-
cacy groups may influence the availability of interven-
tions, enhancing the patient healthcare experience by
incorporating the ‘patient’s voice’ throughout payer
decision-making [57, 66].
One such example illustrated in the literature, is the
decision by NICE (2015) to recommend the use of ninte-
danib plus docetaxel (Vargatef®) as a treatment option
for locally advanced, metastatic or locally recurrent non-
small-cell lung cancer of adenocarcinoma histology. The
drug approval was primarily based on improved survival,
minimal adverse drug effects and fewer detrimental ef-
fects on health-related quality of life (HRQL) compared
to chemotherapy treatment. PRO data suggested that
HRQL, as measured by the EuroQol-5 Dimension (EQ-
5D), the European Organization for Research andTreatment core quality of life questionnaire (EORTC
QLC-C30) and the lung cancer–specific Quality of Life
Questionnaire (EORTC QLQ-LC13) was similar in both
groups [57, 96]. However, the PRO measures also dem-
onstrated better pain management in patients rando-
mised to nintedanib plus docetaxel based on
information from the pain items [57, 96]. Therefore,
additional drug benefits (symptom improvement and tol-
erability) were demonstrated through incorporation of
PRO measurements into the trial, which similarly in-
formed the reimbursement decision. The additional
HRQL benefits may have been missed without the sup-
porting PRO data within this trial.
Clinical decision-making
While reducing the impact of intervention toxicity and the
impact on HRQL is important for drug labelling claims, it
is also an important consideration for choices in clinical
decision-making. According to Goodwin et al. (2003), when
there is medical treatment equivalence, HRQL data has the
potential to inform clinical decision-making by prioritising
quality of life outcomes and reduction in toxicity when
making clinical decisions [56]. The authors conducted a
systematic review of breast cancer clinical trials including
PROs and determined that HRQL contributed to clinical
decision-making within primary management (surgery, ra-
diation and hormone therapies) and symptom control/sup-
portive care setting of breast cancer.
In total, 26 publications presented evidence that PRO
data may help in the selection of optimal treatment, pa-
tient’s symptom experience and management, satisfac-
tion with care and might predict prognosis, which has
the potential to inform clinical decision-making based
on the clinicians’ critical appraisal and interpretation of
the available information [5, 34–36, 38–40, 44–61, 74].
Dirven et al. (2014) conducted a systematic review of
PRO clinical trials in patient with brain tumours and
demonstrated that HRQL can be used alongside overall
and progression-free survival to inform clinical decision-
making. One of the clinical trials included determined
that the combination of concomitant and adjuvant tem-
ozolomide and radiotherapy has become standard care
for newly diagnosed patients with glioblastoma [53].
This combination treatment led to significantly pro-
longed overall and progression-free survival, without
negatively impacting HRQL in the long-term as mea-
sured with the EORTC QLQ-C30 questionnaire
and Brain Cancer Module (BN-20) [53].
Shared decision-making
Shared decision-making is also important and four publi-
cations outlined the potential benefits of including PRO
findings alongside other outcomes such as survival. This
allowed patients and their clinicians to make an informed
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management based on mutual understanding of treatment
objectives and expectations [44, 58, 59, 73].
Sztankay et al. (2017) assessed HRQL during first-line
chemotherapy with pametrexed and maintenance ther-
apy (MT) among patients with advanced non-small cell
lung cancer [73]. First-line chemotherapy for patients
with advanced non-small cell lung cancer was shown to
improve overall progression-free survival. However, as
measured with the EORTC QLQ-C30 and EORTC
QLQ-LC13, MT compared to first-line chemotherapy
was associated with lower HRQL and improvements in
nausea, vomiting, appetite loss, constipation and pain.
This information presented alongside survival data,
allowed patients and clinicians to make real-world in-
formed joint decisions regarding treatment options.
Informed treatment consent
Consent for treatment refers to the authorisation given by
a patient to receive a treatment, once the clinician pre-
sents a diagnosis, relevant treatment options and respect-
ive risks and benefits to the patient [97]. Two publications
discussed the influence of PRO trial data on treatment
consent [39, 49]. Parameswaran et al. (2008) presented a
systematic review of two randomised controlled trials, 9
longitudinal studies and 11 cross-sectional studies. The
authors determined that only 11 studies presented data
that was capable of effectively informing patient consent.
This statement was based on the assessment of the HRQL
methodology of the studies, through the HRQL checklist
by Efficace et al. (2003) [34]. For instance, as measured
with the EORTC-QLQ-C30 and MOS-SF36, one of the
eleven studies determined that surgery for oesophageal
cancer patients has a detrimental impact on quality of life
in the postoperative stage (e.g. anastomic leaks, sepsis and
cardiac and pulmonary complications) and in some cases;
quality of life among survival patients does not improve in
the long term [39]. Therefore, communicating HRQL and
clinical data to patients after the intervention could help
inform patients about relevant information regarding re-
covery and outcomes before undergoing an intervention
and inform the consent process.
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